Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction

A Prospective Cohort Study

Bernard Surial, MD; Charles Béguelin, MD; Jean-Philippe Chave, MD; Marcel Stöckle, MD; Noémie Boillat-Blanco, MD; Thanh Doco-Lecompte, MD; Enos Bernasconi, MD; Jan Fehr, MD; Huldrych F. Günthard, MD; Patrick Schmid, MD; Laura N. Walti, MD; Hansjakob Furrer, MD; Andri Rauch, MD; Gilles Wandeler, MD


J Acquir Immune Defic Syndr. 2020;85(2):227-232. 

In This Article


Switching from TDF to TAF among HIV/HBV-coinfected individuals with renal impairment led to improvements in eGFR, a decline in proteinuria, and to ALT normalization in those with elevated ALT levels. The use of TAF in those individuals seems to be safe and effective, and switching from TDF to TAF should be considered among coinfected individuals with renal impairment or with otherwise unexplained ALT elevations.